Latest Financial Results
FY 2024
Fiscal Year Ended Dec 31, 2024
Latest 10-K
View Latest 10-K
Stock Information
Company Overview
Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, including Phase 1-stage MNPR-101-Zr for imaging advanced cancers and late preclinical-stage MNPR-101 radio-immuno-therapeutic (RIT) for the treatment of advanced cancers. Monopar is building a drug development pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and clinical development stages, leveraging its scientific and clinical experience to help reduce the risk of and accelerate the clinical development of its drug product candidates.
Monopar Therapeutics Inc. Investor Presentation
Investor Contact Information
Company
Monopar Therapeutics Inc.
1000 Skokie Blvd.
Suite 350
Wilmette, IL 60091
T: (847) 388-0349
info@monopartx.com